Quarterly ResultAug 4, 2026, 08:03 AM
High Tide Forecasts Record Q3 Revenue, Gross Profit, Adjusted EBITDA
AI Summary
High Tide Inc. announced preliminary guidance for its third fiscal quarter ended July 31, 2026, projecting record revenue, gross profit, and Adjusted EBITDA. The company expects revenue between C$195.0 million and C$200.0 million, gross profit between C$51.0 million and C$53.5 million, and Adjusted EBITDA between C$15.2 million and C$16.5 million, all exceeding analyst forecasts. Additionally, its German subsidiary, Remexian Pharma GmbH, achieved a record quarterly distribution of over 10 tonnes of medical cannabis.
Key Highlights
- Preliminary Q3 2026 revenue guidance: C$195.0M - C$200.0M.
- Preliminary Q3 2026 gross profit guidance: C$51.0M - C$53.5M.
- Preliminary Q3 2026 Adjusted EBITDA guidance: C$15.2M - C$16.5M.
- Revenue guidance implies 30%-34% year-over-year growth.
- Adjusted EBITDA guidance implies 43%-55% year-over-year growth.
- German subsidiary Remexian Pharma distributed over 10 tonnes of medical cannabis.
- Remexian Pharma's distribution increased 33% sequentially and 60% year-over-year.
- Canadian bricks-and-mortar same-store sales returned to positive in June and July.
Price Impact
More from HITI